CJC-1295 No DAC 5mgCJC-1295 No DAC 5mg
A label commonly used for modified GRF(1–29), distinct from the albumin-binding CJC-1295 studied in published trials.
Answer a short online consultation. A clinician reviews it, and you only pay if treatment is approved. Dispensed by our licensed facility.
What it is
Products labelled CJC-1295 No DAC commonly contain modified GRF(1–29), a synthetic analogue of the active segment of growth hormone-releasing hormone. The label does not ensure a single standardised molecular identity.
Unlike the DAC-containing molecule, this peptide lacks the albumin-binding modification. It acts through the pituitary GHRH receptor, but the exact sequence and formulation must be confirmed.
Why people ask about it
Interest often reflects a preference for shorter hormonal signalling, although a shorter action does not establish better safety or outcomes.
What the science says
The often-cited healthy-volunteer CJC-1295 trials studied the DAC-containing molecule, not a generic No DAC product. Robust outcome trials for modified GRF(1–29) marketed under this name are insufficient to substantiate sleep or body-composition claims.
Is it right for me?
An online consultation and clinician approval must precede payment for No DAC products, with molecular identity and any suspected hormone deficiency reviewed first.
How Welcuren works
Complete a short online consultation about your health and goals.
A clinician reviews your answers, may ask follow-up questions, and decides whether this treatment is appropriate for you.
You only pay once treatment is approved. Our licensed facility then dispatches it with full instructions, on tracked global delivery.
Safety
Growth hormone-axis stimulation may affect glucose control and cause fluid-related symptoms, while product-specific long-term risks are poorly defined. Pituitary lesions, active cancer, pregnancy and breastfeeding need careful consideration; your clinician will advise
Questions
Does No DAC mean the original trial molecule?
No: the published long-acting CJC-1295 molecule included an albumin-binding modification.
What does modified GRF(1–29) refer to?
It describes an altered 29-amino-acid fragment of growth hormone-releasing hormone.
Can No DAC results be inferred from DAC trials?
Different molecular persistence and exposure prevent straightforward transfer of trial conclusions.
Does shorter action establish a safer option?
Duration alone cannot establish comparative safety without appropriate clinical studies.
This information is educational and not a substitute for advice from your clinician. Prescription treatments are only supplied after a clinical consultation.
Often considered together
Many clients start with a blood test so their clinician has a full picture.
AOD-9604 5mgAOD-9604 5mg
AOD-9604 5mg is supplied in a branded pre-filled pen with case, available only following an online consultation and clinician approval.
CJC-1295 + Ipamorelin BlendCJC-1295 + Ipamorelin Blend
A dual-secretagogue blend with uncertain formulation and no robust clinical evidence for the marketed combination.
CJC-1295 with DAC 2mgCJC-1295 with DAC 2mg
An albumin-binding GHRH analogue studied in small human trials for hormonal responses, not proven wellness outcomes.